Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD-885 in Healthy Subjects and Rheumatoid Arthritis Patients
NCT07266207Phase 1Completed
- Sponsor
- Artivila Biopharma
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ARD-885 in rheumatoid arthritis (RA), sponsored by Artivila Biopharma. Primary endpoint: Adverse Events/Severe Adverse Events. Started Dec 2024; status: completed.
02
Drugs
ARD-885
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07266207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266207.